Armata completes Phase II Tailwind study enrollment in US
Armata Pharmaceuticals has completed patient enrollment for its Phase II Tailwind study for inhaled bacteriophage therapy AP-PA02, targeting chronic pulmonary…
Armata Pharmaceuticals has completed patient enrollment for its Phase II Tailwind study for inhaled bacteriophage therapy AP-PA02, targeting chronic pulmonary…
This week on Pipeline Moves, we kick off by looking at the completion of a Phase II/III trial of Pfizer’s…
Regeneron Pharmaceuticals’ gene therapy for otoferlin hearing loss, DB-OTO, has restored hearing to normal in an 11-month-old child within 24…
France-based Sensorion has announced that its hearing loss candidate SENS-401 has a protective effect on early residual hearing loss after…
Sensorion has unveiled promising preliminary results from its Proof of Concept (POC) Phase IIa trial of SENS-401 (Arazasetron) for the…
Altamira Therapeutics has reported that the NASAR clinical trial of Bentrio nasal spray for seasonal allergic rhinitis (SAR) has met…
Lyra Therapeutics has restarted screening and enrolment of patients in its second pivotal Phase III clinical trial, ENLIGHTEN II, of…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Decibel Therapeutics’ clinical trial application (CTA) for initiating a…
Sensorion has reported the enrolment of the first patient in its Phase IIa proof of concept clinical trial of SENS-401…
Lyra Therapeutics has enrolled the first subject in the Phase III ENLIGHTEN II clinical trial to evaluate its investigational product…